Brands
Jio, Samsung win ‘Best Innovation” award
MUMBAI: Reliance Jio Infocomm and Samsung Electronics have announced that they have won the “Best obile Innovation for Emerging Markets” from Global Mobile Awards 2017 at Mobile World Congress 2017 for the digital movement that Jio, with support from Samsung, is bringing to India.
Jio and Samsung’s ongoing effort in transforming India into a digitally empowered society by
overcoming the country’s digital divide has been recognized on the global stage with this prestigious award. The two organizations have focused on reaching the power of communication
and information with free voice and world’s lowest data rates across towns and rural areas through the deployment of the world’s largest greenfield LTE network in India.
“We are pleased to have won this prestigious award in joint effort with Samsung Electronics, who have been a reliable partner in our pursuit to creating a truly Digital India,” said Jio president Jyotindra Thacker. “By continuing to introduce consumer-centric options in our services and much easier access, we hope to bring down India’s digital divide and enable every Indian to benefit from digital life,” he added.
“Today’s achievement signified more than just an award, it is an indicator of the transformation we have brought to India and its people,” said Samsung Electronics president and head of network business Youngky Kim. “Samsung, as Jio’s strategic partner for the realization of Digital India, is pleased to be able to support the process of India taking steps towards becoming a pioneer in the global telecommunications industry.”
Brands
Bayer sues Johnson & Johnson over prostate cancer drug advertisements
Legal dispute begins as Bayer claims rival marketing is based on flawed data
NEW YORK: Bayer has filed a federal lawsuit against Johnson & Johnson (J&J) in New York, alleging that the American pharmaceutical company has used false and misleading advertisements to promote its prostate cancer treatment, Erleada. The dispute centres on claims that Erleada is significantly more effective than Bayer’s competing drug, Nubeqa.
The legal action follows a J&J marketing campaign that cited a 51 per cent reduction in the risk of death for patients using Erleada compared to those on Nubeqa. Bayer contends that these figures are based on a study with severe methodological errors rather than a controlled clinical trial.
Bayer’s legal team argues that J&J’s real-world analysis is fundamentally flawed. According to the complaint, J&J claimed to have 24 months of patient data supporting its conclusions, even though many patients included in the study had reportedly been on the medication for only a few months, raising concerns about the reliability of long-term survival comparisons.
The lawsuit also highlights what Bayer describes as a critical approval gap. For most of the period analysed in J&J’s study, Nubeqa had not yet been approved for the specific indication being evaluated, which Bayer argues makes a direct clinical comparison inappropriate and potentially misleading.
Additionally, Bayer contends that the study suffered from significant sample imbalance. The analysis reportedly included five times as many Erleada patients as Nubeqa patients, a disparity that Bayer says introduced statistical bias and undermined the validity of the findings.
Bayer is pursuing the case under the Lanham Act, the U.S. law governing false advertising and unfair competition. The company is seeking an immediate halt to J&J’s current marketing campaign and is asking the court to require corrective statements to physicians to address what it characterises as inaccurate claims.
Furthermore, Bayer is seeking monetary damages, arguing that the alleged misleading advertisements have resulted in lost revenue and reputational harm to Nubeqa.
Johnson & Johnson has responded by stating that it stands by the integrity of its data and the rigour of its analysis. The case will now proceed through the U.S. District Court for the Southern District of New York.
